Adverse Drug Reaction (ADR) Awareness Week 20-24th November

27th November 2017

As a health professional, you have an integral role to play in identifying ADRs and reporting these to the authorities. The Yellow Card scheme collects reports of adverse incidents associated with medicines and medical devices.

You should report suspected ADRs to all medicines (licensed and unlicensed), including: prescription medicines, vaccines, over-the-counter (OTC) medicines, blood factors and immunoglobulins, herbal remedies,  and homeopathic remedies. For medicines you should report, all serious reactions even if the reaction is well known, all unusual reactions, and all adverse reactions associated with a new medicines (i.e. black triangle scheme). To submit a valid medicine report to the scheme, you need to provide four items of information: an identifiable patient, a suspect reaction, a suspect drug and an identifiable reporter.

Remember, you don’t have to have proof that an adverse event was caused by the medicine, only a suspicion and patients can now also self-report. If you suspect an ADR report it here https://yellowcard.mhra.gov.uk/

More News

SCRIPT eLearning Shortlisted for Prestigious HSJ Patient Safety Award

SCRIPT eLearning is delighted to announce that it has been shortlisted in the ‘Patient Safety Education and Training’ category of the HSJ Patient Safety Awards 2026, recognising its ongoing contribution to improving safety in prescribing and medicines management. The...

Birmingham Education for Health Professional Conference 2026

The SCRIPT team was delighted to present a poster at the Birmingham Education for Health Professional Conference 2026, led by our Research Associate Divya Singh. The poster, titled "eLearning in Multidisciplinary Prescribing Education: A Longitudinal Evaluation...

New Modules Under Development

We are committed to developing and adding new modules to ensure the SCRIPT programme continues to reflect current clinical practice and meets our learners’ changing needs. We have several modules at various stages of development, including Drugs of Addiction and...

Updated module – Diabetes: Antihyperglycaemic Medicines

NICE has recently updated its guidance on ‘Type 2 diabetes in adults: management’. In a change to national guidance modified‑release metformin alongside an SGLT2 inhibitor is now recommended as first‑line treatment for adults with type 2 diabetes mellitus....